We are live on ! Find out more
HQL

abrdn Life Sciences Investors

80 hedge funds and large institutions have $73.9M invested in abrdn Life Sciences Investors in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 15 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

567% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 3

113% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 15

27% more funds holding

Funds holding: 6380 (+17)

27% more capital invested

Capital invested by funds: $58.4M → $73.9M (+$15.5M)

3.74% more ownership

Funds ownership: 17.01%20.75% (+3.7%)

Holders
80
Holders Change
+17
Holders Change %
+26.98%
% of All Funds
1.29%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
32
Reduced
15
Closed
3
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q4 2022 in Review

80 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2022, worth a combined $73.9M — up 27% from $58.4M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new HQL positions and 3 closed out — a net gain of 17 holders — while 32 added to existing stakes and 15 trimmed.

The largest buyer was 1607 Capital Partners, adding an estimated $4.42M. The largest seller was Needham Investment Management, cutting an estimated $2.19M.

  • 80 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2022, up from 63 in Q3 2022.
  • Funds reported $73.9M of abrdn Life Sciences Investors stock for Q4 2022, up 27% quarter-over-quarter.
  • 20 funds opened new abrdn Life Sciences Investors positions in Q4 2022 and 3 closed out, a net change of +17 holders.
  • The largest abrdn Life Sciences Investors buyer in Q4 2022 was 1607 Capital Partners, an estimated $4.42M added.
  • The largest abrdn Life Sciences Investors seller in Q4 2022 was Needham Investment Management, an estimated $2.19M sold.

Based on aggregated 13F filings for Q4 2022.